| All GCR typesa | CAN1/LYP1/ALP1 translocationsb |
---|
Relevant genotype | Rate | 95% CI | Rate | Frequency |
---|
wildtype | 1.1 | < 1-6.2 | ND | ND |
rad51
a
| < 8 | < 7-15 | ND | ND |
rad52
| 138 | 16-267 | ND | ND |
rad59
| 24 | 13-50 | ND | ND |
sgs1
a
| 220 | 144-276 | < 7.3 | 0/30 |
mec3
a
| 46 | 18-75 | < 1.5 | 0/30 |
sgs1 rad59
| 126 | 107-300 | ND | ND |
sgs1 rad59 rad51
| 118 | 49-154 | ND | ND |
sgs1 mec3
a
| 1297 | 1120-2030 | 173 | 20/150 |
sgs1 mec3 rad51
a
| 1491 | NDc | 198 | 4/30 |
sgs1 mec3 rad52
a
| 3168 | NDc | < 23 | 0/136 |
sgs1 mec3 rad59
| 2476 | 1595-3187 | 16 | 1/158 |
sgs1 mec3 rad59 rad51
| 1124 | 734-1460 | 7 | 1/168 |
- a Median rate of cells resistant to canavanine and 5-FOA (Canr 5-FOAr × 10-10). 95% confidence intervals (CIs) for median GCR rates were calculated according to Nair [80], where non-overlapping confidence intervals indicate statistically significant differences between median GCR rates. GCR rates for wildtype [81], sgs1 [82], mec3, sgs1 mec3 [60], rad51, sgs1 mec3 rad51 and sgs1 mec3 rad52 mutants [10] were reported previously and are included for comparison.
- b Rate of accumulating translocations between CAN1, LYP1 and/or ALP1 (Canr 5-FOAr × 10-10). GCR clones from sgs1, mec3, sgs1 mec3, sgs1 mec3 rad51, sgs1 mec3 rad52 were previously screened for CAN1/LYP1/ALP1 translocations [10, 60]. ND, not determined.
- c To determine 95% CIs for sgs1 mec3 rad51 and sgs1 mec3 rad52 mutants, GCR rates were re-measured for the current study. The GCR rate for the sgs1 mec3 rad51 mutant was 1933 × 10-10 (95% CIs: 601-2240 × 10-10) and the GCR rate for the sgs1 mec3 rad52 mutant was 2220 × 10-10 (951-3470 × 10-10). The previously reported rates fall within the 95% CIs determined in the current study.